Australia markets close in 40 minutes

Addex Therapeutics Ltd (ADXN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.83+0.10 (+1.08%)
At close: 11:07AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.72
Open10.03
Bid0.00 x 900
Ask0.00 x 900
Day's range9.71 - 10.03
52-week range8.88 - 37.52
Volume7,712
Avg. volume5,541
Market cap71.35M
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science
    GlobeNewswire

    Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science

    Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and

  • Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021
    GlobeNewswire

    Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

    Geneva, Switzerland, August 2, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and

  • Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
    GlobeNewswire

    Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding

    IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022 Geneva, Switzerland, July 29, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has extended its research collaboration agreement with Indivior PLC (LON: INDV). As part of the extension, Indi